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Background: Fabry disease is an X-linked lysosomal storage disorder caused by α-galactosidase A deficiency
leading to renal, cardiac, cerebrovascular disease and premature death. Treatment with α-galactosidase A (enzyme
replacement therapy, ERT) stabilises disease in some patients, but long term effectiveness is unclear.
Methods: Renal, cardiac, and cerebral outcomes were prospectively studied in males and females with Fabry
disease treated with ERT. Additionally, the occurrence of major cardiac events, stroke, end-stage renal disease and
death was compared to a natural history (NH) cohort meeting treatment criteria.
Results: Of 75 patients on ERT (median treatment duration 5.2 years, range 0.05-11.0), prospective follow-up was
available for 57 adult patients (30 males) and 6 adolescents. Renal function declined in males (-3.4 ml/min/1.73 m2
per year, SE 0.2; p < 0.001) despite ERT, but followed the normal course in females (-0.8 ml/min/1.73 m2 per year,
SE 0.3; p = 0.001). Cardiac mass increased during ERT in males (+ 1.2 gram/m2.7, SE 0.3; p < 0.001), but remained
stable in females (-0.3 gram/m2.7 per year, SE 0.4; p = 0.52). ERT did not prevent the occurrence of cerebral white
matter lesions. Comparison of ERT treated to untreated patients revealed that the odds to develop a first
complication increased with age (OR 1.05 (95% CI: 1.0-1.1) per year, p = 0.012). For development of a first or second
complication the odds declined with longer treatment duration (OR 0.81 (95% CI: 0.68-0.96) per year of ERT,
p = 0.015;OR 0.52 (0.31-0.88), p = 0.014 respectively).
Conclusions: Long term ERT does not prevent disease progression, but the risk of developing a first or second
complication declines with increasing treatment duration. ERT in advanced Fabry disease seems of doubtful benefit.Background
Fabry disease is an X-linked lysosomal storage dis-
order caused by deficiency of α-galactosidase A [1,2]
leading to accumulation of glycosphingolipids, mainly
globotriaosylceramide (Gb3). Males with classical disease
manifestations usually have no residual α- galactosidase A
activity and can present with acroparesthesia, anhidrosis,
angiokeratoma during childhood followed by renal, cardiac
and cerebrovascular complications and early death [3]. The
disease is generally milder in females [4]. Atypical cases,
with preserved residual enzyme activity, can exhibit a
more attenuated course [5]. LysoGb3, a new marker in
Fabry disease, can be used to distinguish patients with an* Correspondence: c.e.hollak@amc.uva.nl
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reproduction in any medium, provided the oratypical phenotype from a classic phenotype [6]. As op-
posed to patients with classic disease manifestations atyp-
ical cases show low plasma lysoGb3 levels [6]. In 2001,
the European Medicines Agency (EMA) authorized two
alfa-Galactosidase A preparations for treatment of Fabry
disease: agalsidase-alfa (ReplagalW Shire HGT) and
agalsidase-beta (FabrazymeW Genzyme Corp). Trials
showed clearance of Gb3 and improvement in pain
[7,8]. Since then only one long-term phase IV study with
a placebo arm was conducted with agalsidase beta [9]. All
other long-term studies lack an untreated comparator.
These studies are often derived from post-marketing drug
registry databases from the Fabry Outcome Survey (FOS,
Shire) or the Fabry Registry (Genzyme). While these data-
bases include a relatively large number of patients, the
datasets are frequently incomplete with considerable vari-
ation in assessments [10]. Studies from these registries
showed decline in renal function in patients with pre-ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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showed cardiac and cerebral manifestations may occur
despite treatment [12,13]. Recently data from a large study
in the UK on six lysosomal storage disorders have been
published, showing a beneficial effect of ERT on LVmass
and renal function, in particular females [14]. Outcomes
of enzyme replacement therapy (ERT) have been com-
pared to historical data from untreated cohorts but these
usually involve more severely affected patients. A compari-
son of the development of clinical complications in equally
affected patients before and after the availability of ERT
has not been performed. This information is vital as
the efficacy of ERT should be clarified and the rationale
for the reimbursement of these costly therapies needs
underpinning. The first objective was to analyze long-
term follow-up of ERT treated Fabry disease patients on
renal, cardiac and cerebrovascular parameters. The sec-
ond objective was to compare the time to occurrence of
major complications in ERT treated patients versus a
natural history cohort meeting treatment criteria.
Patients and methods
Enzyme replacement therapy (ERT) cohort and natural
history (NH) cohort
The Academic Medical Center serves as the Dutch Fabry
disease referral center. Prospective data as well as
historic data were collected from all patients with a
confirmed diagnosis of Fabry disease through enzyme-
activity and DNA analysis. Two cohorts were defined: an
(ERT) cohort and a natural history (NH) cohort (see
below). Patients were classified as typical or atypical pa-
tients on the basis of phenotype, genotype and biochem-
ical data [15]. Both cohorts mainly consisted of patients
with a classical phenotype. A minority consisted of atyp-
ical patients with the R112H and P60L substitutions or
patients with intermediate levels of plasma lysoGb3.
ERT cohort
Prospective data were collected from ERT treated patients
(n = 75) between 1999 and 2010, who received either
agalsidase alfa 0.2 mg/kg/2 weeks or agalsidase beta at a
dose of 0.2 mg/kg/2 weeks or 1.0 mg/kg/2 weeks. Thirteen
patients were treated with 0.2 mg/kg agalsidase beta as
part of a trial [16]. Four patients continued this regimen
while 9 switched to 1.0 mg/kg after 5.2 (1.1-8.1) years.
Current available data are too limited to draw a definitive
conclusion on equality or difference in effectiveness be-
tween agalsidase alfa and agalsidase beta and therefore
these data were combined [16,17].
NH cohort
Data were derived from medical records of Fabry pa-
tients who had a history of complications before ERT
was available or from Fabry patients with an indicationfor ERT who remained untreated after ERT became
available. Only untreated patients meeting treatment
criteria (see below for definition) were included, to pre-
vent bias by indication. Some patients with ‘symptoms’
remained untreated due to individual preferences or be-
cause at that time they did not meet criteria to start
ERT (the criteria changed after 2007). ‘Symptoms’ are
defined as the presence of chronic kidney disease (CKD
1-4), left ventricular hypertrophy (LVH) or cerebral
white matter lesions (WML) and are an indication for
ERT according to the Dutch Fabry guidelines. LVH and
CKD are predictors for cardiac and renal complications
in Fabry disease, and WML for stroke in general [18-20].
Acroparesthesia are not evidently associated with cardiac,
renal or cerebrovascular complications. Thus, patients
with acroparesthesia but without any other ‘symptoms’
were not included in the analysis on development of com-
plications. Microalbuminuria or proteinuria was treated
with ACE-inhibitors and/or angiotensin receptor blockers
(ARB). In addition, anti-coagulants/anti-aggregatory, anti-
arrhythmic and pain medication was instituted following
hospital guidelines.
Data collection and analysis
At least 6 months of follow-up was required for the ana-
lysis of renal function, LVmass and cerebral white matter
lesions during ERT. Prospectively collected data of the
untreated patients meeting treatment criteria were too
limited for a separate analysis. For the analysis of major
complications all patients in the ERT and NH cohort
were included, independent of follow-up duration. We
did so to avoid selection bias by excluding patients that
developed a complication soon after start of ERT, how-
ever for a representative course of renal function, change
in left ventricular mass (LVmass) and development of
cerebral white matter lesions, we only included data
from patients with at least six months of follow-up.
Follow-up period lasted until data lock (December, 2010),
or August 2009/October 2009 in case of dose reduction
due to worldwide Fabrazyme shortage, or death [21]. Base-
line was defined as the data closest to start of ERT: prior
to ERT or with a maximum of 4 weeks thereafter. Renal
function (estimated glomerular filtration rate or eGFR)
was estimated every three to six months using the abbrevi-
ated MDRD equation and the new Schwartz formula in
children up to 16 years of age [22,23]. The creatinine
determinations were calibrated according to the isotope
dilution mass spectroscopy (IDMS)-traceable creatinine
standard. Baseline CKD, microalbuminuria (urinary albu-
min > 30 mg/24 hour) and proteinuria (urinary protein >
300 mg/24 hour) both in two consecutive samples
within at least three months, were defined according to
international quidelines [24]. As measured GFR was not
available, hyperfiltration was defined as eGFR > 135 ml/
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sound and indexed for height according to Devereux [25].
Echocardiograms were performed in the AMC, except for
a few baseline echocardiograms. Left ventricular hyper-
trophy (LVH) in males was defined as LVmass >51 g/m2.7
in males and >48 g/m2.7 in females [26]. In children cri-
teria for pediatrics were used [27]. Cerebral MRIs were
performed yearly. A cerebral white matter lesion was diag-
nosed by a neuroradiologist as a hyperintense white mat-
ter lesion of more than 1 mm in diameter on FLAIR- and
T2-weighted MRI images. Progression was defined as a
new lesion or a volume increase of a pre-existing lesion.
Plasma lysoGb3 levels were measured with a newly devel-
oped method based on tandem mass spectrometry with
isotope-labeled lysoGb3 (5,6,7,8,9,13C5-lysoGb3) as an
internal standard [28].
Major complications were stroke cardiac, complications,
ESRD and death. Stroke was diagnosed by a neurologist.
Cardiac complications included onset of atrial fibrillation,
other arrhythmias necessitating hospitalization, pacemaker
or cardiac defibrillator (ICD) implantation, cardiac conges-
tion necessitating hospitalization, myocardial infarction,
percutaneous coronary intervention, or coronary artery by-
pass graft. ESRD was defined as CKD stage 5 (a GFR < 15
ml/min/1.73 m2), dialysis or renal transplantation.
Ethical approval was requested from the institutional
review board, METC AMC. The institutional review
board stated that ethical approval was not required.
Statistical analysis
Means and standard deviations and/or medians with
ranges were used to summarize continuous variables.
Change of renal function and LVmass was assessed using
repeated measures with random intercepts for each pa-
tient and expressed as mean change per year and stand-
ard error (SE). Slopes of decline of renal function were
calculated per CKD category and LVmass by presence or
absence of LVH. The annual change of LVmass was cal-
culated and compared to baseline LVmass using the
Wilcoxon signed rank test. Therefore, yearly follow-up
time intervals from baseline were defined: follow-up
1 year ± 3 months, 2 years ± 3 months etc. Age at time of
a first (or new) cerebral WML, the first and second major
complication in another organ system was assessed using
Kaplan-Meier curves and the log-rank test was used for
comparison. The contribution of age, gender and ERT
duration on the development of the first and second major
complication was determined. Not meeting the assump-
tion of proportional hazards in Cox regression, multiple
logistic regression was applied instead. ERT duration
was calculated for the time up to the first or second event
or censoring date. For comparison of continuous data
between independent groups the Mann-Whitney U-test
was applied, for dichotomous data the Fisher’s exact testwas used. A p-value of p < 0.05 was considered statisti-




Patients for assessment of renal function, WMLs and
LVmass during ERT
Of the 75 patients on ERT Figure 1A, 68 adults started
ERT above 18 years of age. Three patients in the ERT co-
hort had a R112H or P60L substitution (2 males). In
addition 4 males were suspected to have a more attenu-
ated course of disease based on plasma lysoGb3 levels.
Patients for assessment of major complications
In total, 142 patients (58 males) with complete medical
records on occurrence of complications were studied,
including 26 children (Figure 1B). Of the 100 patients
with ‘symptoms’, 58 started ERT before a complication
occurred (ERT cohort). In 42 untreated patients, data on
development of complications before initiation of ERT
were used (the NH cohort).
The NH cohort included a higher proportion of atyp-
ical patients, also reflected by a lower plasma lysoGb3
(Table 1). The use of ACE-ARB was comparable for both
cohorts at first presentation, though in the ERT cohort the
number of patients with proteinuria was higher and as a
consequence more patients started ACE-inhibitors /ARBs
during follow-up (38% versus 69%, p = 0.002). The more
severely affected patients were significantly older at pres-
entation than those with one symptom only (p < 0.001).
Renal function, left ventricular mass and cerebral white
matter lesions in the ERT cohort
The baseline characteristics are presented in Table 2.
Median follow-up during ERT in adults (n = 57) was 5.5
(range 0.51-10.0) years, in the adolescents 4.7 (2.0-6.8)
years.
Renal function
In 57 adults (initial treatment: agalsidase beta 1.0 mg/kg:
12 males/11 females, agalsidase beta 0.2 mg/kg: 6 males/3
females, agalsidase alfa 0.2 mg/kg: 12 males/13 females) at
least three serum creatinine values (with the exception of
one male with 2 samples) were available 6 months apart.
Males Baseline eGFR in males was 88.5 ± 40.6 ml/min/
1.73 m2 and mean change was -3.4 (SE 0.2) ml/min/1.73
m2 per year, p < 0.001. Twenty males (66.7%) used ACE-
inhibitors or ARB during ERT. Outcome of renal func-
tion is shown in Table 3. Excluding the 5 males with
hyperfiltration the mean decline in the group at in-
creased risk for CKD (n = 5) was -2.2 (SE 0.4) ml/min/
1.73 m2 (p < 0.001) and CKD1 (n = 7) -3.4 (SE 0.4) ml/
B




14 developed a 
complication 
before initiation of 
ERT (NH cohort)
58 ERT initiated  
before first 
complication (ERT  
cohort)
35 no‘symptoms’
7 no complete 
assessments
100 patients with:  
CKD,LVH or WML
75 Fabry patients on ERT 
Follow-up< 6 months due to: death 
(n=4), shortage (n=3), ERT recently 
started (n=5)
63 patients> 6 months of follow-up 
57 adults, data on renal 
function (n=57), LVmass 
(n=53) and/or WMLs (n=50)
6 adolescents , data on 
renal function (n=6), LVmass 
(n=6) and WMLs (n=6)
A
Figure 1 Overview of ERT and non-ERT cohort. A. The flow-chart shows the patients in the ERT cohort for the prospective analysis of renal
function, left ventricular mass and cerebral white matter lesions; B. the flow-chart demonstrates all patients with complete medical records and
the cohorts used for the analysis of the age to the first complication.
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hyperfiltration, one male progressed to CKD stage 2.
Females Baseline eGFR in females, was 86.6 ± 31.3 ml/
min/1.73 m2 and changed with -0.8 (SE 0.3) ml/min/
1.73 m2 per year (p = 0.001). Twenty-three females used
also ACE-inhibitors or ARB (85.2%) during follow-up.
Mean change per year per CKD stage is presented in
Table 3. Only one female showed hyperfiltration; exclu-
sion of this female resulted in a comparable eGFR
change (n = 5) of -0.9 (SE 0.5) (p = 0.06) in the stage at
increased risk for CKD. There was no progression to
CKD stage 2 in the female with hyperfiltration.
Left ventricular mass
Longitudinal data on LVmass were available in 53 adult
patients (27 males, age 37.1 ± 13.0 years, 26 females, age
46.6 ± 12.3 years). Of these patients, 23 used agalsidasebeta 1.0 mg/kg (12 males/11 females), 9 used agalsidase
beta 0.2 mg/kg (6 males/3 females), and 21 used agalsidase
alfa 0.2 mg/kg (9 males/12 females) at start of follow-up.
In total, 43/53 (81.1%) had more than two follow-up
measurements. Males. LVmass increased significantly
with 1.2 (SE 0.3) gram/m2.7 per year (p < 0.001) during a
median follow-up of 5.0 (0.5-10.1) years. LVH was present
in 40.7% (11/27) males at baseline. LVmass increased 1.0
(SE 0.3) g/m2.7 per year in males without LVH at baseline
(p = 0.004) and 1.5 (SE 0.5) g/m2.7 in males with LVH at
baseline (p = 0.008). Further analysis showed that LVmass
did not change in the first four years of ERT compared
to baseline (p = 0.28). After five or more treatment years,
increase was significant (+9.5 ± 11.5 g/m2.7, n = 11, p =
0.016). In the first treatment year LVmass decreased in
7 males, while in 4 males LVmass did not (there was
stabalization or increase). Differences were predicted by
CKD stage only, not by type of ERT, dosage, antibodies,
Table 1 Baseline characteristics of the patients with
‘symptoms’ before the development of a complication,
that received ERT (n = 58) and the NH cohort (n = 42)




Male (%) 21 (50) 27 (46.6) 0.74
Atypical (%) 13 (30.9) 3 (5.2) 0.001
Age at first presentation
at the AMC, mean ± SD
and median (range)
45.0 ± 14.7 36.8 ± 14.1 0.009*
44.5 (10.8-72.2) 40.3 (13.6-71.2)
Plasma lysoGb3 (nM) 5 (0-137) 11 (4-124) <0.001
Proteinuria (%) 8/36 (22.2) 25/57 (43.9) 0.03
ACE-inhibitors/ ARBs
at presentation (%)
8 (19.0) 15 (25.9) 0.43
Current smoking (%) 6 (14.3) 10 (17.2) 0.51
Other co-morbidity (%) 5 3 (5.2) 0.20
Hypertension (%) 9/40 (22.5) 12 (20.7) 0.18
Dyslipidemia (%) 3 (7.1) 0 (0) 0.07
One symptom only
at presentation (%)
16 (38.1) 30 (51.7) 0.58
More than one symptom
or presenting with
a first complication
(ERT not available yet/
before diagnosis) (%)
26 (61.9) 26 (44.8) 0.58
Comorbidity refers to other (chronic) illnesses possibly affecting disease
course. *In the analysis for treatment effect the confounder age was
adjusted for.
Table 2 Baseline characteristics of patients on ERT with





N 30 27 6 (2 males)
Agalsidase alfa 9 10 4
Agalsidase beta 21 17 2
Age start ERT,
mean ± SD and
median (range)
38.9 ± 14.3 46.8 ± 12.3 16.6 ± 0.7
40.2 (18.0-65.3) 47.2 (20.8-71.5) 16.6 (15.9-17.7)
ACE-ARB (%) 8 (26.7) 10 (37.0) 0 (0)
Hypertension 5 (16.7) 8 (29.6) 0 (0)
eGFR (ml/min/1.73 m2) 88.5 ± 40.6 86.6 ± 31.3 150.4 ± 42.8
CKD 1-5 (%) 23 (76.7) 21 (77.8) 3 (50)
LVH (%) 11/27 (40.7) 12/24 (50.0) 0/4 (0)
WML (%) 12/22 (54.5) 21/27 (77.8) 2/6 (33.3)
Dialysis (%) 0 (0) 0 (0) 0 (0)
Kidney transplant (%) 0 (0) 1 (3.7) 0 (0)
Cardiac
complication (%)
4 (13.3) 1 (3.7) 0 (0)
Stroke (%) 2 (6.7) 1 (3.7) 0 (0)
LVH: left ventricular hypertrophy. WML: white matter lesions, CKD 1-5: chronic
kidney disease stage 1-5. The presence of LVH or cerebral white matter lesions
was not known for all patients at baseline.
Rombach et al. Orphanet Journal of Rare Diseases 2013, 8:47 Page 5 of 9
http://www.ojrd.com/content/8/1/47hypertension or age at start of ERT. Males without
LVmass reduction, had CKD stage ≥ 3, those with reduc-
tion in the first year had CKD ≤2, except for one male
with CKD stage 3 (4/4 versus 1/7, p = 0.015). Females. In
females, LVmass changed with -0.3 (SE 0.4) gram/m2.7 per
year (p = 0.52) during a median follow-up of 5.0 years
(range 1.1- 8.0). LVH was present in 50% at baseline. In fe-
males without LVH at baseline, mean change was -0.3 ±
0.5 g/m2.7 per year (p = 0.61) and -0.4 ± 0.6 g/m2.7 (p =
0.48) in those with LVH at baseline. Differences in re-
sponse (13 females had LVmass decline, 13 remained
stable or had an increase) could not be explained by CKD
stage, presence of hypertension, age at start of ERT, type
of ERT or dosage.
White matter lesions
Males Of the 25 males (mean age 37.3 ± 12.9 years, initial
treatment: agalsidase beta 1.0 mg/kg: n = 11, agalsidase
beta 0.2 mg/kg: n = 6, and agalsidase alfa 0.2 mg/kg: n = 8)
with follow-up MRIs, 12 (48%) developed (new) white
matter lesions (WMLs). The median ERT treatment dur-
ation at the time of a new WML or time to follow-up
was 3.1 (0.9-8.1) years. The time to development of
WMLs was not different in males with and withoutbaseline WMLs (p = 0.44). The males without WMLs at
baseline were younger than the males with WMLs at base-
line (p = 0.006).
Females Of the 25 females (mean age 46.6 ± 12.8 years,
initial treatment: agalsidase beta 1.0 mg/kg: n = 11,
agalsidase beta 0.2 mg/kg: n = 3, and agalsidase alfa
0.2 mg/kg n = 11) with follow-up MRIs, seven (28%) de-
veloped (new) white matter lesions during 4.0 (1.0-6.1)
years. The time to appearance of white matter lesions was
not different in the groups with or without baseline white
matter lesions (p = 0.77).
The adolescent cohort
Six adolescents (2 males) started ERT (agalsidase beta
1.0 mg/kg: 1 female, agalsidase alfa 0.2 mg/kg: 2 males/
3 females) before adulthood, because of acroparesthesia,
microalbuminuria and a WML (n = 1), acroparesthesia
and microalbuminuria (n = 2), microalbuminuria (n = 2)
and WML (n = 1). Median age at start of ERT was 16.6
(range 15.9-17.7) years and median ERT follow-up
4.7 (range 2.0-6.8) years. eGFR declined with -7.3 ± 1.0
ml/min/1.73 m2 (p < 0.001). Four demonstrated hyper-
filtration at baseline, none of them progressed to CKD
stage 2. One female and one male developed WMLs;
another female with a previous WML developed an
asymptomatic lacunar infarction. None had LVH at
baseline. LVmass (5/6 with more than two follow-up
measurements) remained stable with an annual change
Table 3 Mean change of eGFR during ERT in 30 male and 27 female patients per CKD stage
CKD stage at start of ERT Males Females
N eGFR change ± SE/year p-value N eGFR change ± SE/year p-value
at increased risk for CKD **(=GFR > 60,
no microalbuminuria or proteinuria)
7 -2.5 ± 0.4* <0.001 6 -1.0 ± 0.5* 0.05
CKD1 (=GFR > 90 and microalbuminuria) 10 -4.5 ± 0.4* <0.001 7 -1.3 ± 0.7 0.07
CKD2 (=GFR 60-90 and microalbuminuria) 4 -2.1 ± 0.3 <0.001 10 -0.3 ± 0.3 0.25
CKD3 (=GFR30-60) 6 -4.1 ± 0.2 <0.001 3 -1.4 ± 0.5 0.015
CKD4(=GFR 15-30) 3 -2.0 ± 0.2 <0.001 1 -3.5 ± 0.3 -
CKD5 (=GFR < 15) 0 0
M=male, F = female. * eGFR change without hyperfiltration (GFR > 135 ml/min/1.73 m2) in males: at increased risk for CKD** (5M): -2.2 ± 0.4 ml/min/1.73 m2
(p < 0.001), CKD 1 (7M) -3.4 ± 0.4 ml/min/1.73 m2 (p < 0.001) and in females: at increased risk for CKD** (5F): 0.9 ± 0.5 (p = 0.06). ** at increased risk for CKD
according to CKD guidelines. The p-value indicates whether the change in renal function is significant.
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developed.
Major complications: development of ESRD, a cardiac
complication, stroke, or death
A first complication occurred in 34/100 patients (22 males,
12 females) (Figure 2). Major complications in the 19 pa-
tients not receiving ERT included a cardiac event (9 males/
4 females), ESRD (1 female) and stroke (3 males/2 fe-
males). In the fifteen patients on ERT (median treatment
duration of 3.2 (range 0.7-7.6) years) a cardiac event
(4 males/3 females), ESRD (3 male/1 female), stroke
(2 males/1 female) and death (1 male, 26 years, sudden
death, cause unknown) occurred. There was no differ-
ence in time to first complication between the NH and
ERT cohort (p = 0.69), nor when excluding atypical pa-
tients, (p = 0.28) (Figure 2A). Age, gender and ERT dur-
ation including all patients in the NH and ERT cohort
contributed to the prediction of a first complication in
both cohorts (Table 4, Figure 2B). The odds for develop-
ing a first complication increased with age (OR 1.05
(95% CI: 1.0-1.1) per year, p = 0.012), and declined with
longer treatment duration (OR 0.81 (95% CI: 0.68-0.96)
per year of ERT, p = 0.015) independent of gender. Exclud-
ing atypical patients also revealed a beneficial effect of
ERT duration (OR 0.71, (95% CI: 0.58- 0.87), p = 0.001).
Of the 33 patients with a first complication and still
alive, 6 were untreated and 27 received ERT. In the NH
cohort, 5/6 patients developed a second complication,
being a cardiac event (1 male), ESRD (1 female), stroke
(1 female) and death (1 male, 61 years, cause of death
peritonitis/sepsis following bowel perforation, 1 female,
76 years, cause of death heart failure). Twenty-seven pa-
tients received ERT (median treatment duration of 2.3
years (0.1-8.5) years up to the second complication or
end of follow-up); 9/27 patients had a second complica-
tion; a cardiac event (2 males/1 female), ESRD (1 male),
stroke (2 males) or died (2 males, 48 and 64 years,
causes of death: cardiac failure, and 1 male, 55 years, cause
of death multiple strokes). The rate of development of asecond complication was similar between the NH and
ERT group (p = 0.72). ERT duration (as opposed to gender
and age) contributed to the prediction of a second compli-
cation (Table 4). The odds ratio without age and gender
resulted in a similar outcome (0.53 (95% CI: 0.34-0.85),
p = 0.008). Excluding the atypical patients (n = 7), did
not alter the conclusions. Of the nine patients who were
still alive after the second complication, four developed
a third complication or died, all within 6 years; two with
and two without treatment.
Discussion
This study suggests that enzyme replacement therapy
with either agalsidase alfa or agalsidase beta has limited
effectiveness on the course of renal, cardiac and cerebral
manifestations. Complications occurred in both treated
and untreated patients with Fabry disease. However,
increased treatment duration reduced the odds of devel-
oping a first and second complication in another organ.
This means that in general, prolonged treatment delays
the occurrence of complications. This is in line with a
placebo-controlled trial showing that the hazard ratio for
developing complications was lower in patients treated
with agalsidase beta compared to placebo [9]. While pa-
tients in that study had advanced Fabry disease, our study
indicates that complications can also not be prevented in
milder affected patients.
Of interest is whether males and females respond dif-
ferently to ERT. In our study females had a stable renal
function resembling the healthy population [29]. Also,
LVmass remained stable in females, while LVmass in-
creased in males. This is in line with previous studies,
showing a more favourable course in females [30,31].
Kidney failure influences cardiac outcome as CKD con-
tributes to increase of LVmass, independent of blood
pressure [32,33]. Here we made a similar observation:
progression of LVmass was primarily seen in males with
advanced renal disease. Presence of cardiac fibrosis may
explain unresponsiveness to ERT [13,34,35]. In our co-
hort, insufficient cardiac (MRI) data were available for
AB
Figure 2 Developing a first complication. The curves show the
percentage without a first complication during follow-up. The small
vertical lines represent censored data (follow-up till the vertical line
without development of a complication). A. Age at time of the first
complication is depicted for the NH cohort and the ERT cohort.
B. The time to the first complication is shown based on the median
ERT duration for the ERT cohort only: patients receiving ERT more
than 4.2 years (13M/16F, age at start of ERT 40.1 (15.9-71.5) years) or
less than 4.2 years (14M/15F, age at start of ERT 41.2 (15.2-60.5
years)). Of note, in the analysis ERT duration was included as a
continuous variable.
Table 4 Multiple logistic regression analysis for the developm
cohort and the development of a second complication in pat
First complication
Odds ratio (95% CI) 1
Age in years 1.05 (1.0-1.1)
Gender (male) 4.45 (1.6-12.1)
ERT duration in years 0.81 (0.68-0.96)
The odds ratio represents the additional risk of developing a complication based on
1Intercept = e-3.024; 2Intercept = e-0.326.
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http://www.ojrd.com/content/8/1/47this analysis. Antibody formation in males is associated
with a less robust decline of plasma lysoGb3, Gb3 and
urinary Gb3, which may reflect worse treatment outcome,
but needs to be studied in larger patient groups [36].
Our study has several limitations. The natural history co-
hort consisted of patients with an indication for ERT who
developed complications before ERT became available or
who remained untreated, thus creating an untreated cohort
with comparable disease severity. It is possible however, that
disease progression in this NH cohort is underestimated, as
not all complications may have been recorded as rigorously
in the pre-ERT era. Alternatively, the inclusion of more
atypical patients in the NH study cohort may underestimate
the effectiveness of ERT. Excluding atypical patients from
the analyses demonstrated a more beneficial effect of ERT
duration. This illustrates that ERT is less effective in patients
with a more attenuated disease course compared to patients
with a classic phenotype. In contrast, the effect of ERT may
have been overestimated, as patients in the ERT cohort re-
ceived improved supportive care.
In this study we combined outcome data for agalsidase
alfa and agalsidase beta. The controversy whether the drugs
are equally effective remains unresolved. Both drugs appear
to have an identical rate of complications at equal dose [16]
and another ongoing study suggests no difference in out-
come at registered dose [17]. Another important issue is
the use of ACE/ARB medication that may have influenced
treatment outcome. In the ERT group more patients had
proteinuria, and during follow-up more patients on ERT
started ACE-ARB medication. As the number of patients
with proteinuria in the NH and ERT group was not equal,
further stratification by ACE/ARB was not performed. Des-
pite these limitations, the most important conclusion that
can be drawn from the current study is that long term out-
come of ERT is of limited effectiveness. Earlier reports
frequently emphasize lack of progression or delay in pro-
gression as important benefits [12,37]. ERT with agalsidase
alfa was reported to lead to substantial and sustained bene-
fits. The data indicated, however, that there was a decline in
renal function despite therapy and no change in left ven-
tricular mass [37]. Similarly, in 58 patients, mainly males,
treated with agalsidase beta for 4.5 years, stabilization of
renal function was reported but patients with a more
rapid decline were left out of the analysis [12]. Smaller,ent of a first complication in patients in the ERT and NH
ients with a previous complication
Second complication
p-value Odds ratio (95% CI) 2 p-value
0.012 1.02 (0.93-1.1) 0.75
0.003 2.8 (0.40-19.6) 0.30
0.015 0.52 (0.31-0.88) 0.014
age, gender and ERT treatment.
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http://www.ojrd.com/content/8/1/47uncontrolled cohort studies have reported on progression
of disease despite treatment in patients with more advanced
renal or cardiac disease, especially in patients with de-
creased renal function and cardiac fibrosis. A better out-
come in less affected patients has been shown [13]. In a
recent study, concerning a large cohort of Fabry disease
patients from the UK, increasing duration of ERT had a
small but beneficial effect on left ventricular mass and on
renal function (in females) [14]. The risk of stroke/TIA
was not influenced by ERT. Interestingly quality of life
scores declined over time, but no correction for disease
severity was made, which makes it difficult to interpret
these data. Also, the authors commented that the study
was weakened by substantial amounts of missing data
[14]. If ERT cannot prevent disease progression in se-
verely affected patients and if longer treatment duration
is associated with decrease of complications, it is tempt-
ing to assume that early therapy is most effective. How-
ever, the results of early treatment in minimally affected
boys, is still awaited (trial number NCT00701415, http://
www.clinicaltrials.gov). In the studied adolescents here,
eGFR declined, LVmass remained stable but WMLs were
not prevented. This suggests that even in patients with
early disease manifestations, progression occurs. In con-
clusion, long term ERT combined with optimal supportive
care (additional interventions and medication) does not
prevent disease progression, but longer treatment duration
may lower the risk of developing additional complications.
The risk of developing a first or second complication de-
clines with increasing treatment duration, but as no short
term beneficial effect of ERT is expected, ERT in advanced
disease seems to be of little benefit.
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